| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 01/27/2005 | WO2005007081A2 Compounds and methods for delivery of prostacyclin analogs |
| 01/27/2005 | WO2005007080A2 Methods and compositions for delivery of catecholic butanes for treatment of tumors |
| 01/27/2005 | WO2005007079A2 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
| 01/27/2005 | WO2005007075A2 Adaptive resynchronization therapy system |
| 01/27/2005 | WO2005007074A2 Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
| 01/27/2005 | WO2005007073A2 Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs |
| 01/27/2005 | WO2005007072A2 Methods and pharmaceutical compositions for healing wounds |
| 01/27/2005 | WO2005007071A2 Skin formulation |
| 01/27/2005 | WO2005007070A2 Stable pharmaceutical composition |
| 01/27/2005 | WO2005007069A2 Soft gel formulations for saquinavir |
| 01/27/2005 | WO2005006899A1 Treatment of male sexual dysfunction |
| 01/27/2005 | WO2004098518A3 Pyrazole-amide compounds useful as kinase inhibitors |
| 01/27/2005 | WO2004093818A3 Apparatus and methods for repetitive microjet drug delivery |
| 01/27/2005 | WO2004091528A3 Delivery systems of homogeneous thermoreversible alginate films |
| 01/27/2005 | WO2004087046A3 TREATMENT OR PREVENTION OF cGMP-DEPENDENT PATHOPHYSIOLOGY WITH A MUTANT VARIANT OF SOLUBLE GUANYLYL CYCLASE |
| 01/27/2005 | WO2004087043B1 Stable ophthalmic formulation containing an antibiotic and a corticosteroid |
| 01/27/2005 | WO2004084829A3 Esterified fatty acid composition |
| 01/27/2005 | WO2004082606A3 Fused pyrrole compounds |
| 01/27/2005 | WO2004082580A3 Photostabilized topical formulations of ketoprofen containing two uv filters |
| 01/27/2005 | WO2004075827A3 Process for the preparation of 2-[(diphenylmethyl) thio] acetamide |
| 01/27/2005 | WO2004073639A3 Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| 01/27/2005 | WO2004073623A9 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 01/27/2005 | WO2004069208A3 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 01/27/2005 | WO2004069164A3 Wireless blood glucose monitoring system |
| 01/27/2005 | WO2004064757A3 Absorption enhancing agents |
| 01/27/2005 | WO2004064747A3 Treating androgen deficiency in female (adif)-associated conditions with sarms |
| 01/27/2005 | WO2004064741A3 Compounds, compositions, and methods |
| 01/27/2005 | WO2004064740A3 Sperm specific lysozyme-like proteins |
| 01/27/2005 | US20050021103 Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
| 01/27/2005 | US20050021090 Method and device for regulation of limbic system of the brain by means of neuro-electrical coded signals |
| 01/27/2005 | US20050020654 Novel PPAR agonists, pharmaceutical compositions and uses thereof |
| 01/27/2005 | US20050020635 C7 carbamoyloxy substituted taxane compositions |
| 01/27/2005 | US20050020633 Nitroxide radioprotector formulations and methods of use |
| 01/27/2005 | US20050020595 Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| 01/27/2005 | US20050020557 Synergistic mixture; anticancer agents; mammary glands |
| 01/27/2005 | US20050020556 Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| 01/27/2005 | US20050020546 Pharmaceutical compositions comprising active vitamin D compounds |
| 01/27/2005 | US20050020534 Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| 01/27/2005 | US20050020522 Induce mitrosis and smooth muscle proliferation; administering to cell or tissue a polynucleotide which codes endothelial growth factor |
| 01/27/2005 | US20050020500 Glycosaminoglycan-polypeptide complex; antiarthritic agents |
| 01/27/2005 | US20050020481 Ion channel modulating compounds and uses thereof |
| 01/27/2005 | US20050019752 Novel chimeric rev, tat, and nef antigens |
| 01/27/2005 | US20050019397 Cellulosic fiber containing composition |
| 01/27/2005 | US20050019392 Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| 01/27/2005 | US20050019375 Consumable farinaceous food comprising alpha -cyclodextrin and fat having same amounts of calories and cholesterol; reduced bioavailability, increased high density lipoproteins |
| 01/27/2005 | US20050019374 Plasticizer, film former, bulking agent, and pH controlling agent; |
| 01/27/2005 | US20050019329 Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein |
| 01/27/2005 | US20050019326 Antiinflammatory agents; tissue injury; autoimmune disease; anticancer agents |
| 01/27/2005 | US20050019301 Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition |
| 01/27/2005 | US20050019292 Epilatory compositions |
| 01/27/2005 | US20050019287 Stable aluminum / zirconium antiperspirant solution free of amino acid and polyhydric alcohol |
| 01/27/2005 | US20050019285 Cosmetic composition of foundation type for making up dark skins |
| 01/27/2005 | US20050015847 Compositions and methods for preventing infection |
| 01/27/2005 | CA2851309A1 Compounds and methods for delivery of prostacyclin analogs |
| 01/27/2005 | CA2800212A1 Histone deacetylase inhibitors and methods of use thereof |
| 01/27/2005 | CA2771944A1 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| 01/27/2005 | CA2736406A1 Compositions comprising diethanolamine salts of trepostinil in the treatment of pulmonary hypertension and other cardiovascular diseases |
| 01/27/2005 | CA2573060A1 Asymmetric disulfides and methods of using same |
| 01/27/2005 | CA2533314A1 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 01/27/2005 | CA2533177A1 Treatment of male sexual dysfunction |
| 01/27/2005 | CA2533165A1 Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
| 01/27/2005 | CA2532542A1 Treatment or prevention of damage due to radiation exposure |
| 01/27/2005 | CA2532352A1 Methods and pharmaceutical compositions for healing wounds |
| 01/27/2005 | CA2532229A1 Use of parthenolide derivatives as antileukemic and cytotoxic agents |
| 01/27/2005 | CA2532212A1 Pharmaceutical compositions for topical application |
| 01/27/2005 | CA2531564A1 Pharmaceutical composition for inhibiting acid secretion |
| 01/27/2005 | CA2531322A1 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/27/2005 | CA2531065A1 Pharmaceutical compositions |
| 01/27/2005 | CA2528383A1 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
| 01/26/2005 | EP1500390A1 Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| 01/26/2005 | EP1499589A1 Derivatives of n-phenyl(piperidin-2-yl)methyl benzamide, the preparation method thereof and application of same in therapeutics |
| 01/26/2005 | EP1084109B1 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 01/26/2005 | EP0854702B1 Antimicrobial compositions containing a c 3-c 6 alcohol |
| 01/26/2005 | CN1571770A Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same |
| 01/26/2005 | CN1571675A Treatment and diagnosis of insulin-resistant states |
| 01/26/2005 | CN1571670A Treating sexual desire disorders with flibanserin |
| 01/26/2005 | CN1571669A Novel combination |
| 01/26/2005 | CN1571658A Pharmaceutical formulation comprising (R)-bicalutamide |
| 01/26/2005 | CN1186340C C10 carbonate substituted taxanes as antitumor agents |
| 01/25/2005 | US6846485 Fish serine proteinase and their pharmaceutical and cosmetic use |
| 01/25/2005 | CA2146442C Anti-inflammatory factor, method of isolation, and use |
| 01/20/2005 | WO2005005458A1 A method for cleaving proteins |
| 01/20/2005 | WO2005004818A2 Heterocyclic compounds and their use as anticancer agents |
| 01/20/2005 | WO2005004817A2 Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases |
| 01/20/2005 | WO2005004816A2 Color stabilization of hydroquinone hydroxyethyl ether products |
| 01/20/2005 | WO2005004814A2 Sirt1 and genetic disorders |
| 01/20/2005 | WO2005004812A2 Gelled starch compositions and methods of making gelled starch compositions |
| 01/20/2005 | WO2005004811A2 Self-crosslinkable poly(caprolactone fumarate) |
| 01/20/2005 | WO2005004809A2 Multivalent carriers of bi-specific antibodies |
| 01/20/2005 | WO2005004808A2 TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS |
| 01/20/2005 | WO2005004806A2 Combination therapy for treating chronic inflammatory diseases |
| 01/20/2005 | WO2005004805A2 Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| 01/20/2005 | WO2005004804A2 Compositions and methods for selective dissolution of nascent intravascular blood clots |
| 01/20/2005 | WO2005004803A2 Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
| 01/20/2005 | WO2005004802A2 N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| 01/20/2005 | WO2005004800A2 Trypanosome derived apoptotic factors (taf) |
| 01/20/2005 | WO2005004799A2 β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF |
| 01/20/2005 | WO2005004798A2 Methods for treating lentivirus infections |
| 01/20/2005 | WO2005004797A2 Pharmaceutical dosage forms having overt and covert markings for identification and authentification |
| 01/20/2005 | WO2005004795A2 Compositions and methods for targeted drug delivery |